Evidence map›Paper›PMID 40000629›Full record

ArticleNature communications2025

Structural basis for lipid-mediated activation of G protein-coupled receptor GPR55.

Tobias Claff, Rebecca Ebenhoch, Jörg T Kley, Aniket Magarkar, Herbert Nar, Dietmar Weichert

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rebecca EbenhochBoehringer Ingelheim Pharma GmbH & Co. KG, Global Medicinal Chemistry, Biberach an der Riß, Germany.ORCID http://orcid.org/0000-0003-4304-7434
Jörg T KleyBoehringer Ingelheim Pharma GmbH & Co. KG, Global Medicinal Chemistry, Biberach an der Riß, Germany.ORCID http://orcid.org/0000-0001-5543-6387
Aniket MagarkarBoehringer Ingelheim Pharma GmbH & Co. KG, Global Medicinal Chemistry, Biberach an der Riß, Germany.ORCID http://orcid.org/0000-0003-3385-964X
Herbert NarBoehringer Ingelheim Pharma GmbH & Co. KG, Global Medicinal Chemistry, Biberach an der Riß, Germany.ORCID http://orcid.org/0000-0002-3878-6964
Dietmar WeichertBoehringer Ingelheim Pharma GmbH & Co. KG, Global Medicinal Chemistry, Biberach an der Riß, Germany. dietmar.weichert@boehringer-ingelheim.com.ORCID http://orcid.org/0000-0002-0694-7671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GPR55 is an orphan G protein-coupled receptor (GPCR) and represents a promising drug target for cancer, inflammation, and metabolic diseases. The endogenous activation of lipid GPCRs can be solely mediated by membrane components and different lipids have been proposed as endogenous activators of GPR55, such as cannabinoids and lysophosphatidylinositols. Here, we determine high-resolution cryo-electron microscopy structures of the activated GPR55 in complex with heterotrimeric G

Indexed as

Receptors, CannabinoidReceptors, G-Protein-CoupledBinding SitesCryoelectron MicroscopyHEK293 CellsHumansLigandsLysophospholipidsModels, MolecularProtein BindingGPR55 protein, humanLigandslysophosphatidylinositolLysophospholipidsReceptors, CannabinoidReceptors, G-Protein-Coupled

Identifiers

PMID40000629
PMCPMC11861906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.